The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pulmonary fibrosis
Publications
High-dose busulfan and the risk of pulmonary mortality after autologous stem cell transplant.
Clinical transplantation 2006 Nov-Dec;20;783-7 — 2006 Nov-Dec — 783-7
25-year study of lung fibrosis following carmustine therapy for brain tumor in childhood.
Chest 2004 Sep;126;1007 — 2004 Sep — 1007
Interstitial pulmonary fibrosis following busulfan therapy.
The American journal of medicine 1961 Jul;31;134-9 — 1961 Jul — 134-9
1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis.
Neurosurgery 1980 Dec;7;560-5 — 1980 Dec — 560-5
Busulfan lung. Report of two cases and review of the literature.
The American journal of roentgenology, radium therapy, and nuclear medicine 1974 Jan;120;151-6 — 1974 Jan — 151-6
[Busulfan-induced pneumopathy].
Revue des maladies respiratoires 1987;4;3-10 — 1987 — 3-10
Fatal radiation pneumonia following subclinical busulfin injury.
AJR. American journal of roentgenology 1977 Jan;128;15-8 — 1977 Jan — 15-8
Busulfan lung.
American journal of diseases of children (1960) 1977 Jun;131;650-2 — 1977 Jun — 650-2